Pegus Cheryl 4

What Happened
Cheryl Pegus, a non-employee director of Boston Scientific Corporation (BSX), was granted deferred stock units (DSUs) on May 7, 2026. She received two awards: 3,800 DSUs and 1,281 DSUs (total 5,081 DSUs) reported at $0.00 per share on the Form 4. Footnotes explain the awards reflect an aggregate implied value of $287,500 ($215,000 + $72,500) based on the closing price used to calculate unit counts. These were awards/compensation grants (not purchases or sales).

Key Details

• Transaction date: May 7, 2026. Form 4 filed May 11, 2026 (4 days after the grant).
• Grants: 3,800 DSUs (footnote F4; reflects $72,500) and 1,281 DSUs (footnote F2; reflects $215,000).
• Reported price: $0.00 per unit (derivative award — deferred stock units).
• Total units granted: 5,081 DSUs; total implied value per filing footnotes: ~$287,500.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting/issuance: Footnotes F3/F4 state DSUs vest in full upon the next annual meeting of stockholders; vested shares will be issued following the reporting person’s separation from Board service under the Non-Employee Director Deferred Compensation Plan.
• Purpose: F4 notes part of the DSUs were granted in lieu of 50% of yearly cash compensation (non-employee director retainer and committee chair retainers).
• Filing timeliness: Filed May 11 for a May 7 grant (a 4-day gap). Form 4s are typically due within two business days of transaction, so investors may note the reporting lag.

Context
Deferred stock units are a form of compensation for non-employee directors that represent the company’s commitment to issue shares later (they are derivatives, not immediate share purchases). Such awards are routine director compensation and do not, by themselves, signal personal buying or selling intent in the market.